COVID-19 pandemic has put strengths and weaknesses of healthcare systems including pharmaceuticals in a new light, both in Europe around the world and. Health systems responded effectively and cohesively to many challenges with new hospital beds created, countries allocating resources to regions in need, fostering collaboration in the pharmaceutical sector and among health care professionals aimed at bringing vaccines to European citizens. All these positive and encouraging efforts to respond adequately during the crisis create space for further development of European co-operation in post-COVID time.

In recent years we have seen how rare diseases, digital therapeutics, personalized medicine, cell and gene therapies, and other new therapeutic approaches have stretched our data and methodological capabilities. During this session panelists will consider what useful lessons we have learned from the SARS-CoV-2 pandemic so far, and what health systems would require from the HEOR community to respond to key challenges associated with these innovative solutions in emerging frontiers. A special focus will be put on an international partnership and dialogue aimed at special populations and technologies which have important implications for a range of European healthcare decisions, from regulatory pathways, pricing and reimbursement to managed entry agreements.

*Speakers to be added as confirmed!